Wednesday October 10, 4:01 pm Eastern Time
Press Release
SOURCE: Lexicon Genetics Incorporated
Lexicon Genetics Licenses Patented Gene Targeting
Technology to Pfizer Inc.
THE WOODLANDS, Texas, Oct. 10 /PRNewswire/ -- Lexicon Genetics Incorporated
(Nasdaq: LEXG - news) announced today that it has granted a non-exclusive, internal
research use license to Pfizer Inc. (NYSE: PFE - news) under the patent covering the use of
Lexicon's isogenic DNA technology in gene targeting. Pfizer already holds a non-exclusive
license from Lexicon for internal research use of Lexicon's patented positive-negative
selection technology. Financial details were not disclosed.
``We are pleased that Pfizer has taken an additional license to our patented gene targeting
technologies and believe the increased interest in our sublicense reflects the growing value
that is associated with in vivo target validation,'' said Arthur T. Sands, M.D., Ph.D.,
President and Chief Executive Officer of Lexicon.
Lexicon Genetics Incorporated is a drug discovery company of the post- genome era, using
gene knockout technology to define the functions of genes for the discovery of
pharmaceutical products. Lexicon is using this technology to fuel drug discovery programs in
cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and
obesity. Lexicon has established drug discovery alliances and functional genomics
collaborations with leading pharmaceutical and biotechnology companies, research institutes
and academic institutions throughout the world to commercialize its technology and further
develop its discoveries. Additional information about the Company is available through
Lexicon's corporate website, www.lexicon-genetics.com .
This press release contains ``forward-looking statements,'' including statements about
Lexicon's growth and future operating results, discovery and development of products,
strategic alliances, and intellectual property, as well as other matters that are not historical
facts or information. These forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to achieve its operational objectives,
obtain patent protection for its discoveries and establish strategic alliances, that may cause
Lexicon's actual results to be materially different from any future results expressed or implied
by such forward-looking statements. Information identifying such important factors is contained under ``Factors Affecting
Forward-Looking Statements'' and ``Business - Risk Factors'' in Lexicon's annual report on Form 10-K for the year ended
December 31, 2000, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or
revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Lexicon Genetics Incorporated |
